This announcement is a separate document:
ネクセラファーマ:当社提携先であるニューロクライン社による健常成人を対象としたNBI-1117567の第1相臨床試験開始のお知らせ
Sosei Group: Notice of commencement of phase 1 clinical trial of NBI-1117567 targeting healthy adults by Neurocline, our partner
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.